Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

ImmunoGen, Inc. · 2016
ClinicalTrials.gov · Datasets · License: Public Domain · 2016
Open Source ↗
adcantibody
epithelial ovarian cancer, primary peritoneal cancer, fallopian tube cancer, imgn853, adc, antibody drug conjugate, immunogen, antibody, phase 1, folate receptor alpha, mirvetuximab, interventional
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 803462
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.